000284352 001__ 284352
000284352 005__ 20260212105836.0
000284352 0247_ $$2doi$$a10.3389/fncel.2025.1677505
000284352 0247_ $$2pmid$$apmid:41602576
000284352 0247_ $$2pmc$$apmc:PMC12832296
000284352 037__ $$aDZNE-2026-00123
000284352 041__ $$aEnglish
000284352 082__ $$a610
000284352 1001_ $$0P:(DE-HGF)0$$aHartung, Theresa$$b0$$eFirst author
000284352 245__ $$aNon-hematopoietic erythropoietin splice variant is produced in the diseased human brain and confers neuroprotection.
000284352 260__ $$aLausanne$$bFrontiers Research Foundation$$c2025
000284352 3367_ $$2DRIVER$$aarticle
000284352 3367_ $$2DataCite$$aOutput Types/Journal article
000284352 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770812576_18492
000284352 3367_ $$2BibTeX$$aARTICLE
000284352 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284352 3367_ $$00$$2EndNote$$aJournal Article
000284352 520__ $$aErythropoietin (EPO) is a pleiotropic cytokine with important functions in neuronal development and neuroprotection, but hematopoietic effects limit the therapeutic application of EPO in neurological diseases. We discovered human endogenous EPO splice variants that are non-hematopoietic but cytoprotective. Here, we demonstrate at the single-cell level that an alternative splice variant lacking exon 3 (hS3) is expressed in the human brain and is upregulated above EPO mRNA levels in ischemic and inflammatory neurological diseases. Conversely, hS3 mRNA expression is reduced below EPO levels in neurodegenerative disease. In an oxygen-glucose deprivation (OGD) model of ischemia, a single dose of cell-free synthesized constant glycosylated active hS3 protects neuronal cultures derived from human induced pluripotent stem cells (hiPSC) and human embryonic stem cells (hESC) more effectively than EPO. We identify the D-helix as a key functional domain of hS3 and demonstrate that the neuroprotective effect is enhanced by PD29, a novel small peptide derived from the D-helix of hS3. Long-term hS3 administration increases the neuroprotective effects in the OGD model by dose-dependent differential expression of apoptosis-related protein-coding genes and long non-coding RNAs (lncRNAs). In addition, our results suggest that hS3 induces early cell cycle inhibition without impairing differentiation of hiPSC and hESC into neuronal subtypes. In conclusion, EPO splice variant hS3 is part of the endogenous neuroprotective system in the human brain with significant therapeutic potential.
000284352 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000284352 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000284352 650_7 $$2Other$$aalternative splicing
000284352 650_7 $$2Other$$acell-free glycoprotein synthesis
000284352 650_7 $$2Other$$aerythropoietin
000284352 650_7 $$2Other$$ain situ hybridization
000284352 650_7 $$2Other$$aneuroprotection
000284352 650_7 $$2Other$$aoxygen glucose deprivation
000284352 650_7 $$2Other$$apluripotent stem cells
000284352 7001_ $$aFreyer, Dorette$$b1
000284352 7001_ $$aZemella, Anne$$b2
000284352 7001_ $$aRadbruch, Helena$$b3
000284352 7001_ $$aWeiner, January$$b4
000284352 7001_ $$0P:(DE-HGF)0$$aEl-Din, Jasmin Jamal$$b5
000284352 7001_ $$aMeisel, Andreas$$b6
000284352 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b7$$eLast author$$udzne
000284352 773__ $$0PERI:(DE-600)2452963-1$$a10.3389/fncel.2025.1677505$$gVol. 19, p. 1677505$$p1677505$$tFrontiers in cellular neuroscience$$v19$$x1662-5102$$y2025
000284352 8564_ $$uhttps://pub.dzne.de/record/284352/files/DZNE-2026-00123.pdf$$yOpenAccess
000284352 8564_ $$uhttps://pub.dzne.de/record/284352/files/DZNE-2026-00123.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000284352 909CO $$ooai:pub.dzne.de:284352$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000284352 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000284352 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000284352 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000284352 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000284352 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-14
000284352 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000284352 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT CELL NEUROSCI : 2022$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-12-04T12:35:29Z
000284352 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-12-04T12:35:29Z
000284352 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000284352 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-12-04T12:35:29Z
000284352 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT CELL NEUROSCI : 2022$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-14
000284352 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-14
000284352 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x0
000284352 980__ $$ajournal
000284352 980__ $$aVDB
000284352 980__ $$aUNRESTRICTED
000284352 980__ $$aI:(DE-2719)5000007
000284352 9801_ $$aFullTexts